Subjects With Subjective Cognitive Decline: 18F-Florbetaben Positron Emission Tomography Study
Status:
Unknown status
Trial end date:
2019-03-15
Target enrollment:
Participant gender:
Summary
Phase II, open-label clinical trial with a medicinal product. A total of 30 subjects will be
included in the study.
All participants will receive a single intravenous dose of 300 MBq of FBB. A 20-minute PET
image should be acquired starting at approximately 90 minutes after intravenous injection of
FBB.
The present proposal aims are: to assess safety of a single dose of FBB followed by PET scan
in individuals with subjective cognitive decline (SCD), to determine the number of SCD
subjects with positive visual FBB-PET scan, to determine the number of SCD subjects with
positive standardized uptake value ratios (SUVRs) of FBB-PET scan and to explore the cortical
pattern of amyloid deposition in SCD subjects.